A Prospective, Multicentre, Longitudinal Disease Registry of Indian Patients with Chronic Kidney Disease, with and without Dialysis, to assess the Clinical management of Anaemia

Chronic kidney disease (CKD) is a significant public health issue worldwide, characterized by a reduction in estimated glomerular filtration rate (eGFR) to less than 60 ml/min/1.73 m², as well as structural or functional renal abnormalities. One of the kidneys’ essential functions is the production of erythropoietin, a signaling molecule that stimulates red blood cell production in response to decreased oxygen levels in the blood. Thus, haemoglobin (Hb) levels are typically lower in CKD patients compared to the general population. (Sofue T et al., 2024).

Anaemia is a common and serious complication of chronic kidney disease (CKD), affecting a significant proportion of patients as CKD progresses. It is associated with increased morbidity, reduced quality of life, and higher mortality rates (Portolés et al., 2021). The primary causes of Anaemia in CKD include reduced erythropoietin production, iron deficiency, and chronic inflammation (Hain et al., 2023; Shaikh et al., 2024).

Management of anaemia in CKD varies in India based on whether the patient is on dialysis. According to the KDIGO guidelines, the use of erythropoiesis-stimulating agents (ESAs) is recommended for patients with anemia associated with chronic kidney disease (CKD). Furthermore, the guidelines emphasize the importance of iron supplementation to enhance the efficacy of ESAs, particularly in cases of iron deficiency with careful considerations. (Babitt JL et al., 2012).

For non-dialysis-dependent CKD patients, treatment primarily involves oral or intravenous iron supplements and erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa, or epoetin alfa. (Shaikh et al., 2024; Biju et al., 2024).

This prospective, multicenter longitudinal disease registry aims to collect comprehensive data on the clinical characteristics, outcomes and usage trends associated with various treatment modalities for managing Anaemia in CKD patients. The registry will provide valuable insights to guide clinical decision-making and improve the management of Anaemia in CKD across India.